EWTX insider ownership: who sold, why, and what they still hold

What stands out

Jonathan Fox bought 11K shares for $199K, first on Nov 11, 2025.Purchase, Nov 11, 2025

Alan Russell sold $2.1M of stock with no disclosed trading plan. The filings don't state a reason.Largest such sale, Nov 12, 2025

A share of stake is shown for 0 of the 6 officers and directors who sold. 15 are left out

Left out: Kevin Koch, Michael Carruthers, Joanne Donovan, Behrad Derakhshan, Alan Russell, Jonathan Fox, John Moore, Laura Brege, Badreddin Edris, Jonathan Root, Peter Thompson, Arlene Morris, Robert Blaustein, Michael Nofi and Christopher Martin (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Alan Russell

Chief Scientific Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$10.3M77% planned, 3% to cover taxes 21% no plan disclosed

Joanne Donovan

CMO

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.6M94% planned, 6% to cover taxes

Badreddin Edris

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$3.4MDisclosed plan

Kevin Koch

President and CEO, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$785KTo cover taxes

Behrad Derakhshan

Chief Business Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$223KTo cover taxes

All 6 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Aug 13, 2026Joanne Donovan sold 2.9K shares ($127K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Joanne Donovan CMO	2,919	$43.41	n/a	n/a	Aug 13, 2026	Aug 14, 2026

Outside holders, reported separately

Peter Thompson and Jonathan Root reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Edgewise Therapeutics, Inc. CEO selling stock?

Yes. Kevin Koch sold 18K shares ($785K) in the past 12 months, none of it under a trading plan disclosed in the filings.

Why are Edgewise Therapeutics, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 80% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 9% were to cover taxes and 11% had no disclosed plan. A trading plan schedules sales in advance.

Are any Edgewise Therapeutics, Inc. insiders buying?

Yes. 1 officer or director reported 1 purchase in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold6 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Alan Russell Chief Scientific Officer, Director	$10.3M 306K shares	Not confirmed share of stake is being verified. Why	77% under a disclosed plan, 3% to cover taxes 21% no plan disclosed
Joanne Donovan CMO	$4.6M 131K shares	Not confirmed share of stake is being verified. Why	94% under a disclosed plan, 6% to cover taxes
Badreddin Edris Director	$3.4M 115K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Kevin Koch President and CEO, Director	$785K 18K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Behrad Derakhshan Chief Business Officer	$223K 5.1K shares	Not confirmed share of stake is being verified. Why	To cover taxes
John Moore General Counsel	$220K 5K shares	Not confirmed share of stake is being verified. Why	To cover taxes

Board members representing outside shareholders, reported separately: Peter Thompson, Jonathan Root. Details

The full ownership picture0 of 15 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

Kevin Koch

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Kevin Koch are complete.

President and CEO, Director

n/a

−18K

n/a

Vesting, gifts, unvested awards and holding lines for Kevin Koch

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kevin Koch are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
431,250	$17.05	Aug 12, 2034	$11.4M
41,545	$0.18	Aug 8, 2027	$1.8M
525,000	$13.39	Aug 12, 2035	$15.8M
200,000	$43.56	Aug 12, 2036	$0

Estimate: options held × ($43.41 − strike price), using the most recent insider trade price on Form 4 (Aug 13, 2026), not a market close.

Michael Carruthers

Chief Financial Officer

n/a

Vesting, gifts, unvested awards and holding lines for Michael Carruthers

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michael Carruthers are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
40,990	$1.93	Dec 15, 2030	$1.7M
138,750	$17.05	Aug 12, 2034	$3.7M
127,122	$0.71	Sep 1, 2030	$5.4M
161,250	$13.39	Aug 12, 2035	$4.8M

Estimate: options held × ($43.41 − strike price), using the most recent insider trade price on Form 4 (Aug 13, 2026), not a market close.

Joanne Donovan

CMO

n/a

−131K

n/a

Vesting, gifts, unvested awards and holding lines for Joanne Donovan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joanne Donovan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
75,000	$7.08	Aug 17, 2033	$2.7M
138,750	$17.05	Aug 12, 2034	$3.7M
168,750	$13.39	Aug 12, 2035	$5.1M
65,000	$43.56	Aug 12, 2036	$0

Estimate: options held × ($43.41 − strike price), using the most recent insider trade price on Form 4 (Aug 13, 2026), not a market close.

Behrad Derakhshan

Chief Business Officer

n/a

−5.1K

n/a

Vesting, gifts, unvested awards and holding lines for Behrad Derakhshan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Behrad Derakhshan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
102,949	$1.93	Dec 15, 2030	$4.3M
138,750	$17.05	Aug 12, 2034	$3.7M
92,929	$1.93	Dec 15, 2030	$3.9M
180,000	$13.39	Aug 12, 2035	$5.4M
100,000	$43.56	Aug 12, 2036	$0

Estimate: options held × ($43.41 − strike price), using the most recent insider trade price on Form 4 (Aug 13, 2026), not a market close.

Alan Russell

Chief Scientific Officer, Director

n/a

−306K

n/a

Vesting, gifts, unvested awards and holding lines for Alan Russell

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alan Russell are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,347,565	$0.18	Jun 27, 2032	$58.3M
138,750	$17.05	Aug 12, 2034	$3.7M
1,456,580	$0.18	Jun 27, 2032	$63.0M
168,750	$13.39	Aug 12, 2035	$5.1M
1,077,717	$0.18	Jun 27, 2032	$46.6M
65,000	$43.56	Aug 12, 2036	$0

Estimate: options held × ($43.41 − strike price), using the most recent insider trade price on Form 4 (Aug 13, 2026), not a market close.

Jonathan Fox

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jonathan Fox

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jonathan Fox are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,594	$17.13	Jun 10, 2034	$541K
30,000	$14.68	Jun 16, 2035	$862K
16,377	$35.59	Jun 5, 2036	$128K

Estimate: options held × ($43.41 − strike price), using the most recent insider trade price on Form 4 (Aug 13, 2026), not a market close.

John Moore

General Counsel

n/a

−5K

n/a

Vesting, gifts, unvested awards and holding lines for John Moore

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Moore are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
41,636	$0.71	Sep 1, 2030	$1.8M
93,162	$1.93	Dec 15, 2030	$3.9M
138,750	$17.05	Aug 12, 2034	$3.7M
161,250	$13.39	Aug 12, 2035	$4.8M
65,000	$43.56	Aug 12, 2036	$0

Estimate: options held × ($43.41 − strike price), using the most recent insider trade price on Form 4 (Aug 13, 2026), not a market close.

Laura Brege

Director

n/a

Vesting, gifts, unvested awards and holding lines for Laura Brege

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Laura Brege are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,594	$17.13	Jun 10, 2034	$541K
30,000	$14.68	Jun 16, 2035	$862K
16,377	$35.59	Jun 5, 2036	$128K

Estimate: options held × ($43.41 − strike price), using the most recent insider trade price on Form 4 (Aug 13, 2026), not a market close.

Badreddin Edris

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Badreddin Edris are complete.

Director

n/a

−115K

n/a

Vesting, gifts, unvested awards and holding lines for Badreddin Edris

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Badreddin Edris are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,594	$17.13	Jun 10, 2034	$541K
30,000	$14.68	Jun 16, 2035	$862K
8,188	$35.59	Jun 5, 2036	$64K

Estimate: options held × ($43.41 − strike price), using the most recent insider trade price on Form 4 (Aug 13, 2026), not a market close.

Jonathan Root

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jonathan Root

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jonathan Root are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,594	$17.13	Jun 10, 2034	$541K
30,000	$14.68	Jun 16, 2035	$862K
16,377	$35.59	Jun 5, 2036	$128K

Estimate: options held × ($43.41 − strike price), using the most recent insider trade price on Form 4 (Aug 13, 2026), not a market close.

Peter Thompson

Director

n/a

Vesting, gifts, unvested awards and holding lines for Peter Thompson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Peter Thompson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,594	$17.13	Jun 10, 2034	$541K
30,000	$14.68	Jun 16, 2035	$862K
16,377	$35.59	Jun 5, 2036	$128K

Estimate: options held × ($43.41 − strike price), using the most recent insider trade price on Form 4 (Aug 13, 2026), not a market close.

Arlene Morris

Director

n/a

Vesting, gifts, unvested awards and holding lines for Arlene Morris

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Arlene Morris are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
34,311	$20.34	May 6, 2034	$791K
20,594	$17.13	Jun 10, 2034	$541K
30,000	$14.68	Jun 16, 2035	$862K
16,377	$35.59	Jun 5, 2036	$128K

Estimate: options held × ($43.41 − strike price), using the most recent insider trade price on Form 4 (Aug 13, 2026), not a market close.

Robert Blaustein

Chief Development Officer

n/a

Vesting, gifts, unvested awards and holding lines for Robert Blaustein

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Blaustein are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
160,000	$27.39	Jan 21, 2035	$2.6M
105,000	$13.39	Aug 12, 2035	$3.2M

Estimate: options held × ($43.41 − strike price), using the most recent insider trade price on Form 4 (Aug 13, 2026), not a market close.

Michael Nofi

Chief Financial Officer

n/a

Vesting, gifts, unvested awards and holding lines for Michael Nofi

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michael Nofi are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
262,500	$18.28	Nov 10, 2035	$6.6M
48,750	$43.56	Aug 12, 2036	$0

Estimate: options held × ($43.41 − strike price), using the most recent insider trade price on Form 4 (Aug 13, 2026), not a market close.

Christopher Martin

Director

n/a

Vesting, gifts, unvested awards and holding lines for Christopher Martin

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher Martin are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
45,150	$22.34	Nov 19, 2035	$951K
16,377	$35.59	Jun 5, 2036	$128K

Estimate: options held × ($43.41 − strike price), using the most recent insider trade price on Form 4 (Aug 13, 2026), not a market close.

Holdings and share of stake for Edgewise Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$19.5M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $19.5M across 580,488 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $15.6M · 80%

20%

The lighter segment is sales with no plan disclosed in the filing ($3.9M), including tax-related sales outside a plan.

No plan disclosed · $2.1M

Sales with no 10b5-1 plan and no tax reference in the filing. $2.1M of it is Alan Russell. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Alan Russell, Nov 12, 2025

Taxes

$1.8M of sales (9.1%) cite tax obligations in their footnotes. Example: John Moore, Aug 12, 2026

Purchases · 1 buyer (1 trade)

1 officer or director bought shares in this period, in 1 trade(Form 4 code P, leaving out rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust). Across all their filings on record there are 3 purchase trades.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Alan Russell Chief Scientific Officer, Director	306K	$10.3M	77%	53%	Nov 12, 2025 to Aug 12, 2026
Joanne Donovan CMO	131K	$4.6M	94%	24%	Mar 27, 2026 to Aug 13, 2026
Badreddin Edris Director	115K	$3.4M	100%	17%	Jan 21, 2026 to Jan 21, 2026
Kevin Koch President and CEO, Director	18K	$785K	0%	4%	Aug 12, 2026 to Aug 12, 2026
Behrad Derakhshan Chief Business Officer	5.1K	$223K	0%	1%	Aug 12, 2026 to Aug 12, 2026
John Moore General Counsel	5K	$220K	0%	1%	Aug 12, 2026 to Aug 12, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$2.1M	$0	$0	$2.1M
Dec 2025	$0	$0	$0	$0
Jan 2026	$3.4M	$3.4M	$0	$0
Feb 2026	$0	$0	$0	$0
Mar 2026	$1.2M	$1.2M	$0	$0
Apr 2026	$926K	$926K	$0	$0
May 2026	$2.1M	$2.1M	$0	$0
Jun 2026	$0	$0	$0	$0
Jul 2026	$7.9M	$7.9M	$0	$0
Aug 2026	$1.9M	$127K	$1.8M	$0
Sep 2026	$0	$0	$0	$0
Oct 2026	$0	$0	$0	$0

Board members representing outside shareholders (2)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member	Held Oct 16, 2025	Sold	Held Oct 16, 2026	Still held
Peter Thompson ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Peter Thompson are complete. Director	n/a	0	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Peter Thompson Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Peter Thompson are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)
Jonathan Root ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jonathan Root are complete. Director	n/a	0	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Jonathan Root Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jonathan Root are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)

Is this normal? Selling year by year4 earlier years to compare with

More than usual: about 1.7x the 4-year average. 6 insiders sold; the average is 5 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 16, 2026 Latest 12 months	580K	6	$19.5M
Oct 16, 2025 1 year earlier	318K	7	$7.2M
Oct 16, 2024 2 years earlier	645K	6	$13.3M
Oct 17, 2023 3 years earlier	13K	6	$116K
Oct 17, 2022 4 years earlier	351K	2	$4.2M
Oct 17, 2021 5 years earlier · filings don't cover the whole year	120K	1	$2.2M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty15 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Edgewise Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology201 filings on record, 34 filed in the 12-month period, and how we read them

All 201 Forms 3, 4 and 5 on record for Edgewise Therapeutics, Inc. (SEC CIK 1710072), filed from Mar 25, 2021 to Oct 2, 2026; 34 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (6)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
ORBIMED ADVISORS LLC	Apr 4, 2025	15,252,867 shares, last reported balance as of Apr 3, 2025
Marc Semigran	Dec 27, 2024	6,716 shares, last reported balance as of Dec 24, 2024
Novo Holdings A/S	Sep 16, 2022	6,071,703 shares, last reported balance as of Sep 14, 2022
James Flynn	Mar 30, 2021	3,933,137 shares, last reported balance as of Mar 30, 2021
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.	Mar 30, 2021	681,812 shares, last reported balance as of Mar 30, 2021
Kenneth Harrison		No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Edgewise Therapeutics, Inc. insiders sold $19.5M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Edgewise Therapeutics, Inc. CEO selling stock?

Why are Edgewise Therapeutics, Inc. insiders selling?

Are any Edgewise Therapeutics, Inc. insiders buying?

The evidence

No plan disclosed · $2.1M

Taxes

Purchases · 1 buyer (1 trade)

Sales by month